Cannabinoid Hyperemesis Syndrome : Public Health Implications and a Novel Model Treatment Guideline
INTRODUCTION: Cannabinoid hyperemesis syndrome (CHS) is an entity associated with cannabinoid overuse. CHS typically presents with cyclical vomiting, diffuse abdominal pain, and relief with hot showers. Patients often present to the emergency department (ED) repeatedly and undergo extensive evaluations including laboratory examination, advanced imaging, and in some cases unnecessary procedures. They are exposed to an array of pharmacologic interventions including opioids that not only lack evidence, but may also be harmful. This paper presents a novel treatment guideline that highlights the identification and diagnosis of CHS and summarizes treatment strategies aimed at resolution of symptoms, avoidance of unnecessary opioids, and ensuring patient safety.
METHODS: The San Diego Emergency Medicine Oversight Commission in collaboration with the County of San Diego Health and Human Services Agency and San Diego Kaiser Permanente Division of Medical Toxicology created an expert consensus panel to establish a guideline to unite the ED community in the treatment of CHS.
RESULTS: Per the consensus guideline, treatment should focus on symptom relief and education on the need for cannabis cessation. Capsaicin is a readily available topical preparation that is reasonable to use as first-line treatment. Antipsychotics including haloperidol and olanzapine have been reported to provide complete symptom relief in limited case studies. Conventional antiemetics including antihistamines, serotonin antagonists, dopamine antagonists and benzodiazepines may have limited effectiveness. Emergency physicians should avoid opioids if the diagnosis of CHS is certain and educate patients that cannabis cessation is the only intervention that will provide complete symptom relief.
CONCLUSION: An expert consensus treatment guideline is provided to assist with diagnosis and appropriate treatment of CHS. Clinicians and public health officials should identity and treat CHS patients with strategies that decrease exposure to opioids, minimize use of healthcare resources, and maximize patient safety.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
The western journal of emergency medicine - 19(2018), 2 vom: 20. März, Seite 380-386 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lapoint, Jeff [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 27.08.2018 Date Revised 16.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5811/westjem.2017.11.36368 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM282157409 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM282157409 | ||
| 003 | DE-627 | ||
| 005 | 20231225033258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5811/westjem.2017.11.36368 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0940.xml |
| 035 | |a (DE-627)NLM282157409 | ||
| 035 | |a (NLM)29560069 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lapoint, Jeff |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cannabinoid Hyperemesis Syndrome |b Public Health Implications and a Novel Model Treatment Guideline |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.08.2018 | ||
| 500 | |a Date Revised 16.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Cannabinoid hyperemesis syndrome (CHS) is an entity associated with cannabinoid overuse. CHS typically presents with cyclical vomiting, diffuse abdominal pain, and relief with hot showers. Patients often present to the emergency department (ED) repeatedly and undergo extensive evaluations including laboratory examination, advanced imaging, and in some cases unnecessary procedures. They are exposed to an array of pharmacologic interventions including opioids that not only lack evidence, but may also be harmful. This paper presents a novel treatment guideline that highlights the identification and diagnosis of CHS and summarizes treatment strategies aimed at resolution of symptoms, avoidance of unnecessary opioids, and ensuring patient safety | ||
| 520 | |a METHODS: The San Diego Emergency Medicine Oversight Commission in collaboration with the County of San Diego Health and Human Services Agency and San Diego Kaiser Permanente Division of Medical Toxicology created an expert consensus panel to establish a guideline to unite the ED community in the treatment of CHS | ||
| 520 | |a RESULTS: Per the consensus guideline, treatment should focus on symptom relief and education on the need for cannabis cessation. Capsaicin is a readily available topical preparation that is reasonable to use as first-line treatment. Antipsychotics including haloperidol and olanzapine have been reported to provide complete symptom relief in limited case studies. Conventional antiemetics including antihistamines, serotonin antagonists, dopamine antagonists and benzodiazepines may have limited effectiveness. Emergency physicians should avoid opioids if the diagnosis of CHS is certain and educate patients that cannabis cessation is the only intervention that will provide complete symptom relief | ||
| 520 | |a CONCLUSION: An expert consensus treatment guideline is provided to assist with diagnosis and appropriate treatment of CHS. Clinicians and public health officials should identity and treat CHS patients with strategies that decrease exposure to opioids, minimize use of healthcare resources, and maximize patient safety | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antiemetics |2 NLM | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 650 | 7 | |a Cannabinoids |2 NLM | |
| 700 | 1 | |a Meyer, Seth |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Charles K |e verfasserin |4 aut | |
| 700 | 1 | |a Koenig, Kristi L |e verfasserin |4 aut | |
| 700 | 1 | |a Lev, Roneet |e verfasserin |4 aut | |
| 700 | 1 | |a Thihalolipavan, Sayone |e verfasserin |4 aut | |
| 700 | 1 | |a Staats, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Kahn, Christopher A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The western journal of emergency medicine |d 2007 |g 19(2018), 2 vom: 20. März, Seite 380-386 |w (DE-627)NLM189618582 |x 1936-9018 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2018 |g number:2 |g day:20 |g month:03 |g pages:380-386 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5811/westjem.2017.11.36368 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2018 |e 2 |b 20 |c 03 |h 380-386 | ||